Statements (76)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:monoclonal_antibody
|
gptkbp:accessories |
logistical issues during distribution
|
gptkbp:administered_by |
intravenous infusion
|
gptkbp:administration_guidelines |
administered as soon as possible after diagnosis
|
gptkbp:approves |
gptkb:FDA
November 2020 |
gptkbp:availability |
available in multiple countries
|
gptkbp:business_model |
adhered to in trials
|
gptkbp:can_be_combined_with |
gptkb:imdevimab
|
gptkbp:class |
antiviral agent
|
gptkbp:clinical_trial |
gptkb:United_States
gptkb:Regeneron_Pharmaceuticals Phase 3 randomized controlled trials positive efficacy results multiple phases conducted open for eligible participants |
gptkbp:clinical_trial_phase_results |
Phase 3 results published
|
gptkbp:clinical_use |
post-exposure prophylaxis
|
gptkbp:collaboration |
healthcare providers
|
gptkbp:collaborations |
with academic institutions
|
gptkbp:developed_by |
gptkb:Regeneron_Pharmaceuticals
|
gptkbp:distribution |
managed by federal agencies
allocated by government agencies |
gptkbp:dosage_form |
solution for infusion
|
gptkbp:duration |
single administration
|
gptkbp:eligibility |
must meet specific criteria
|
gptkbp:feedback |
generally positive
|
gptkbp:financial_support |
available for eligible patients
|
gptkbp:funding |
funded by government grants
|
gptkbp:healthcare |
facilitated through healthcare systems
|
https://www.w3.org/2000/01/rdf-schema#label |
casirivimab
|
gptkbp:impact |
significant in COVID-19 management
|
gptkbp:indication |
mild to moderate COVID-19
|
gptkbp:interacts_with |
other monoclonal antibodies
|
gptkbp:invention |
gptkb:Regeneron_Pharmaceuticals
|
gptkbp:is_effective_against |
reduces hospitalization rates
|
gptkbp:is_monitored_by |
monitor for allergic reactions
recommended after administration |
gptkbp:marketed_as |
gptkb:REGEN-COV
|
gptkbp:mechanism_of_action |
neutralizes the virus
|
gptkbp:part_of |
gptkb:REGEN-COV
|
gptkbp:patient_education |
informed about potential side effects
|
gptkbp:patient_population |
high-risk patients
|
gptkbp:pharmacokinetics |
binds to the spike protein
half-life of approximately 20 days |
gptkbp:price |
varies by provider
|
gptkbp:provides_guidance_on |
outpatient
recommended for certain patients updated regularly based on new data |
gptkbp:publication |
published in medical journals
|
gptkbp:regulatory_compliance |
Emergency Use Authorization
based on clinical trial results |
gptkbp:research_focus |
COVID-19 variants
COVID-19 treatment options |
gptkbp:research_output |
reduction in viral load
|
gptkbp:route_of_administration |
subcutaneous injection
|
gptkbp:safety |
collected from clinical trials
|
gptkbp:safety_features |
generally well tolerated
|
gptkbp:safety_measures |
ongoing post-marketing surveillance
|
gptkbp:service_frequency |
single dose
|
gptkbp:side_effect |
infusion-related reactions
mandatory for healthcare providers |
gptkbp:supply_availability |
limited supply during peak demand
|
gptkbp:supply_chain |
gptkb:monoclonal_antibody
|
gptkbp:supply_limitations |
due to high demand
|
gptkbp:targets |
SARS-Co V-2 virus
|
gptkbp:treatment |
improved recovery rates
established for administration. shown in clinical studies |
gptkbp:type_of_insurance |
covered by many insurance plans
|
gptkbp:used_for |
treatment of COVID-19
|
gptkbp:bfsParent |
gptkb:REGEN-COV
gptkb:Regen-Cov gptkb:REGN-COV2 |
gptkbp:bfsLayer |
5
|